by Peter Schmid, Hope S Rugo, Sylvia Adams, Andreas
Schneeweiss, Carlos H Barrios, Hiroji Iwata, Véronique Diéras, Volkmar
Henschel, Luciana Molinero, Stephen Y Chui, Vidya Maiya, Amreen Husain, Eric P
Winer, Sherene Loi, Leisha A Emens, IMpassion130 Investigators
The Lancet Oncology: ARTICLES| VOLUME
21, ISSUE 1, P44-59, JANUARY 01, 2020
Consistent with the first interim analysis, this second
interim overall survival analysis of IMpassion130 indicates no significant
difference in overall survival between the treatment groups in the
intention-to-treat population but suggests a clinically meaningful overall
survival benefit with atezolizumab plus nab-paclitaxel in patients with PD-L1
immune cell-positive disease. However, this positive result could not be
formally tested due to the prespecified statistical testing hierarchy. For
patients with PD-L1 immune cell-positive metastatic triple-negative breast
cancer, atezolizumab plus nab-paclitaxel is an important therapeutic option in
a disease with high unmet need.
